Target intelligence / Profile preview

X-linked inhibitor of apoptosis protein messenger RNA 3' untranslated region (XIAP mRNA 3'UTR)

Target
XIAP mRNA 3'UTR
Molecular classification
Messenger RNA, Regulatory RNA element
01

Overview

The XIAP mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the messenger RNA encoding the X-linked inhibitor of apoptosis protein (XIAP), also known as BIRC4 (UniProt P98170). XIAP is a potent member of the inhibitor of apoptosis (IAP) family that directly binds and inhibits caspases 3, 7, and 9, thereby blocking the execution of programmed cell death (PubMed 16418198). The 3'UTR serves as a platform for post-transcriptional regulation, containing numerous binding sites for microRNAs (miRNAs) such as miR-24 and miR-7, which control the stability and translation efficiency of the XIAP transcript (PubMed 20603077, PubMed 23812434). In many cancers, XIAP is overexpressed, contributing to tumor cell survival, poor prognosis, and resistance to chemotherapy or radiation (PubMed 19103603). Therapeutic strategies targeting the XIAP mRNA, including the 3'UTR, utilize antisense oligonucleotides (ASOs) or miRNA mimics to promote mRNA degradation or inhibit translation. By reducing XIAP protein levels, these interventions lower the threshold for apoptosis and sensitize malignant cells to pro-apoptotic stimuli. Clinical candidates like AEG35156 have been developed to target the XIAP mRNA transcript to induce apoptosis in refractory tumors, while experimental miRNA-based therapies specifically focus on the 3'UTR regulatory sites (PubMed 19103603, PubMed 20603077).

Other names
BIRC4 mRNA 3'UTRIAP3 mRNA 3'UTRX-linked inhibitor of apoptosis protein 3' untranslated regionBaculoviral IAP repeat-containing protein 4 mRNA 3'UTR
02

Mechanism of action

Downregulation of XIAP protein expression through antisense-mediated mRNA degradation or translational repression by targeting regulatory sequences within the mRNA transcript, particularly the 3' untranslated region.

03

Biological functions

Apoptosis regulationPost-transcriptional regulationmRNA stabilityTranslational control
04

Disease associations

CancerLeukemiaLymphomaSolid tumorsInflammatory disorders
05

Safety considerations

Off-target hybridization effectsInnate immune activation by oligonucleotidesSystemic delivery challengesPotential for hepatotoxicity
06

Interacting drugs

AEG35156 (Antisense oligonucleotide)

3 more in the full profile.

07

Biomarkers

XIAP mRNA expression levelsXIAP protein levelsCaspase-3 activityCaspase-7 activityCaspase-9 activity

Beyond the preview

Go deeper on X-linked inhibitor of apoptosis protein messenger RNA 3' untranslated region (XIAP mRNA 3'UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on X-linked inhibitor of apoptosis protein messenger RNA 3' untranslated region (XIAP mRNA 3'UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call